ML-016 / BrYet - LARVOL DELTA

BrYet US, Inc. Receives Approval to Initiate in Australia a First-in-Human Phase 1/2 Trial of ML-016 in Advanced Cancers with Lung and/or Liver Involvement (ACCESS Newswire) - "The open-label, dose-escalation and expansion study...is authorized to commence in Australia with the University of the Sunshine Coast (UniSC) Clinical Trials as the lead site. BrYet expects the trial enrollment to begin in early 2026."

New P1/2 trial • Solid Tumor